Targeted therapies in advanced differentiated thyroid cancer. Issue 8 (September 2015)

• Record Type: Journal Article
• Authors: Carneiro, Raquel M.; Carneiro, Benedito A.; Agulnik, Mark; Kopp, Peter A.; Giles, Francis J.
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 8(2015)
• Page Start: 690
• Page End: 698
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.06.002
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title id="st005">Highlights</title> <sec> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0005">Sorafenib and lenvatinib are approved for advanced differentiated thyroid cancer.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0010">MAPK and PI3K/AKT/mTOR pathways play a central role in differentiated thyroid cancer.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0015">Combination of BRAF and MEK inhibitors is being investigated in thyroid cancer.</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0020">The TCGA characterized papillary thyroid cancer into BRAF- and RAS-driven tumors.</p> </list-item> <list-item id="o0025"> <label></label> <p id="p0025">Redifferentiation agents have an important potential for thyroid cancer treatment.</p> </list-item> </list> </p> </sec> </abstract>